Influence of Low-Dose Ritonavir With and Without Darunavir on the Pharmacokinetics and Pharmacodynamics of Inhaled Beclomethasone
- 1 July 2013
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 63 (3), 355-361
- https://doi.org/10.1097/qai.0b013e31829260d6
Abstract
Objective: To identify an alternative inhaled corticosteroid to fluticasone propionate that can be safely coadministered with HIV protease inhibitors, the safety and pharmacokinetics of beclomethasone dipropionate (BDP) and its active metabolite, beclomethasone 17-monopropionate (17-BMP), in combination with ritonavir (RTV) and darunavir/ritonavir (DRV/r) were assessed. Design: Open-label, prospective, randomized pharmacokinetic and pharmacodynamic study in healthy volunteers. Methods: Thirty healthy volunteers received inhaled 160 μg bid BDP for 14 days and were then randomized (1:1:1) into 3 groups: group 1 (control) remained on BDP alone for 28 days, group 2 received 100 mg bid BDP + RTV for 28 days, and group 3 received 600/100 mg bid BDP + DRV/r for 28 days. Pharmacokinetic sampling for 17-BMP was performed on days 14 and 28, and pharmacokinetic parameter values were compared within patients and between groups. Cortisol stimulation testing was also performed on days 1, 14, 28, and 42 and compared within and between groups. Results: Geometric mean ratios (day 28:day 14) (90% confidence interval) for 17-BMP area under the concentration–time curve in groups 1, 2, and 3, respectively, were 0.93 (0.81 to 1.06, P = 0.27), 2.08 (1.52 to 2.65, P = 0.006), and 0.89 (0.68 to 1.09, P = 0.61). There were no significant reductions in serum cortisol levels within or between groups (P > 0.05). Conclusions: DRV/r did not increase 17-BMP exposure, whereas RTV alone produced a statistically significant but clinically inconsequential 2-fold increase in 17-BMP exposure. Adrenal suppression was not observed in any of the study groups. These data suggest that BDP can be safely coadministered with DRV/r and likely other RTV-boosted protease inhibitors.Keywords
This publication has 24 references indexed in Scilit:
- Cushing syndrome due to ritonavir–fluticasone interactionCMAJ : Canadian Medical Association Journal, 2012
- Technical details influence the diagnostic accuracy of the 1 μg ACTH stimulation testActa Endocrinologica, 2010
- Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96Antiviral Therapy, 2009
- Adrenal suppression and Cushing's syndrome secondary to an interaction between ritonavir and fluticasone: a review of the literatureHIV Medicine, 2008
- Overview of boosted protease inhibitors in treatment-experienced HIV-infected patientsJournal of Antimicrobial Chemotherapy, 2007
- In vitro metabolism of beclomethasone dipropionate, budesonide, ciclesonide, and fluticasone propionate in human lung precision-cut tissue slicesRespiratory Research, 2007
- BIOTRANSFORMATION OF FLUTICASONE: IN VITRO CHARACTERIZATIONDrug Metabolism and Disposition, 2006
- Exogenous glucocorticoid excess as a result of ritonavir–fluticasone interactionInternal Medicine Journal, 2005
- Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in manBritish Journal of Clinical Pharmacology, 2001
- Reproducibility of the cortisol response to stimulation with the low dose (1 μg) of ACTHClinical Endocrinology, 1999